Climb Bio, Inc. CLYM Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $46.71M+226% | $14.34M-7.0% | $15.41M-41.2% | $26.21M+15.9% | ||
| $21.17M+32.1% | $16.03M-35.5% | $24.86M+31.4% | $18.92M+53.2% | ||
| $67.88M-17.2% | $82.02M+104% | $40.28M-10.8% | $45.14M+26.5% | ||
| -$67.88M+17.2% | -$82.02M-104% | -$40.28M+10.8% | -$45.14M-26.5% | ||
| $8.03M-1.1% | $8.12M+57.5% | $5.16M— | —— | ||
| -$59.85M+19.0% | -$73.9M-110% | -$35.12M+22.4% | -$45.24M+4.7% | ||
| -$0.88— | —— | -$1.31+14.4% | -$1.53— | ||
| -$67.79M— | —— | —— | —— | ||
| -$67.88M+17.2% | -$82.02M-104% | -$40.28M+10.8% | -$45.14M-26.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Climb Bio, Inc. profitable?
- Climb Bio, Inc. is not currently profitable: it reported a net loss of $52.8M over the trailing twelve months.
- What is Climb Bio, Inc.'s earnings per share?
- Climb Bio, Inc.'s diluted EPS over the trailing twelve months is $-0.77.
- Where does Climb Bio, Inc.'s income statement data come from?
- Every line is extracted from Climb Bio, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.